Elsevier

Clinica Chimica Acta

Volume 447, 20 July 2015, Pages 66-70
Clinica Chimica Acta

The prognostic value of plasma soluble CD40 ligand levels in patients with nasopharyngeal carcinoma

https://doi.org/10.1016/j.cca.2015.05.015Get rights and content

Highlights

  • Plasma sCD40L level is enhanced in nasopharyngeal carcinoma.

  • sCD40L is correlated with stage progression of nasopharyngeal carcinoma.

  • sCD40L is associated with long-term survival of nasopharyngeal carcinoma.

  • sCD40L is an independent prognostic predictor of nasopharyngeal carcinoma.

Abstract

Background

Serum soluble CD40 ligand (sCD40L) concentrations are increased in patients with nasopharyngeal carcinoma (NPC). This study further evaluated the relationship between plasma sCD40L concentrations and long-term survival of NPC.

Methods

Plasma sCD40L concentrations of 312 patients and 312 healthy controls were determined using an ELISA. The associations of plasma sCD40L concentrations with 5-year overall survival, progression-free survival, distant metastasis-free survival, and locoregional relapse-free survival were investigated by univariate and multivariate analyses.

Results

Plasma sCD40L concentrations were substantially higher in patients than in healthy subjects and also correlated highly with tumor classification, lymph node classification and tumor node metastasis stage. sCD40L emerged as an independent predictor for 5-year overall survival, progression-free survival, distant metastasis-free survival, and locoregional relapse-free survival using univariate and multivariate Cox regression analysis.

Conclusions

High plasma sCD40L concentration is correlated with stage progression of NPC as well as associated with poor survival of NPC. It is suggested that sCD40L should have the potential to be a prognostic biomarker for NPC.

Introduction

CD40 ligand (CD40L) is a transmembrane protein of the tumor necrosis factor family, mainly expressed on the surface of monocytes, macrophages, T cells, B cells, platelets, and endothelial cells [1], [2], [3], [4], [5]. The CD40–CD40L co-stimulatory pathway possesses an important role in the production of some cytokines like interleukin-10 and interleukin-12, which modulate antitumor responses [6], [7]. Activation of the CD40/CD40L pathway also enhances the procoagulant activity of tumor cells through an up-regulation of tissue factor expression [8], [9]. In addition, many tumor cells also express CD40 [10], [11]. It was suggested that CD40L signaling may play a crucial role in cancer occurrence and development [12], [13].

CD40L can be cleaved from the cell surface of activated T-lymphocytes and platelets, releasing a soluble CD40L (sCD40L) which is biologically active [14], [15]. sCD40L can interact with CD40, resulting in promoting inflammatory and prothrombotic responses [16], [17], [18], [19], [20], [21], [22]. Circulating sCD40L concentrations are increased in a great deal of human diseases such as acute coronary syndrome, severe sepsis and pancreatitis [23], [24], [25], [26], [27], [28], [29], [30], [31]. High sCD40L concentrations in peripheral blood have also been found in patients with pancreatic ductal adenocarcinoma and lung cancer [32], [33]. Moreover, increased serum sCD40L concentrations are reported to be associated highly with poor survival of pancreatic ductal adenocarcinoma [32]. A recent research has shown that serum sCD40L concentrations are increased in patients with nasopharyngeal carcinoma (NPC) [34]. However, at present there is a paucity of data available on the relationship between circulating sCD40L concentrations and NPC prognosis.

Section snippets

Study population

Patients with pathologically proven and previously untreated NPC were eligible for this study. Other criteria included > 18 years and receiving complete radical radiotherapy with or without chemotherapy. The exclusion criteria included previous malignant diagnoses, concurrent malignancies, secondary tumors, severe infection and systemic autoimmune disease. Finally, this study included 312 consecutive NPC patients who were recruited at Department of Otorhinolaryngology, The First Affiliated

Study population characteristics

This study recruited 312 NPC patients and 312 healthy subjects. These patients included 232 males and 80 females. Among them, 87 patients had an age of ≥ 50 years and 225 patients had an age of < 50 years. 148 patients had smoking history and 133 patients had alcohol consumption. Theses controls included 220 males and 92 females. Among them, 80 controls had an age of ≥ 50 years and 232 controls had an age of < 50 years. 135 controls had smoking history and 125 controls had alcohol consumption. There

Discussion

The main findings of the current study were that pretreatment plasma sCD40L concentrations were increased in NPC patients compared with healthy individuals; enhanced pretreatment plasma sCD40L concentrations were correlated highly with tumor classification, lymph node classification and tumor node metastasis stage; and increased pretreatment plasma sCD40L concentrations independently predicted 5-year OS, TFS, LRFS and DMFS of NPC patients using a multivariate Cox's proportional hazard analysis.

Conclusions

This study suggests that increased pretreatment plasma sCD40L levels are associated with stage progression and shorter survival time. Thus, pretreatment sCD40L level is a potential factor for predicting long-term survival of NPC patients.

Acknowledgment

This project was supported by the National Natural Science Foundation of China (Grant No. 81472210, 81472346, 81401874, 81001212), The Science and Technology Foundation of Zhejiang Province (Grant NO. 2012C33011) and the National Natural Science Foundation of Zhejiang Province (Grant No.LQ14H160009). The authors thank all staffs in Department of Otorhinolaryngology, The First Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China) for their technical support.

References (47)

  • G. Murugaiyan et al.

    Differential CD40/CD40L expression results in counteracting antitumor immune responses

    J Immunol

    (2007)
  • A. Amirkhosravi et al.

    Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity

    Blood Coagul Fibrinolysis

    (2002)
  • E. Lindmark et al.

    Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression

    Arterioscler Thromb Vasc Biol

    (2000)
  • G. Pirozzi et al.

    CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth

    Int Immunol

    (2000)
  • J. Pammer et al.

    CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma

    Am J Pathol

    (1996)
  • R. Elgueta et al.

    Molecular mechanism and function of CD40/CD40L engagement in the immune system

    Immunol Rev

    (2009)
  • F. Mach et al.

    Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40–CD40 ligand signaling in atherosclerosis

    Proc Natl Acad Sci U S A

    (1997)
  • S.X. Anand et al.

    Membrane-associated CD40L and sCD40L in atherothrombotic disease

    Thromb Haemost

    (2003)
  • L. Zhou et al.

    CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity

    Thromb Haemost

    (1998)
  • A. Hezi-Yamit et al.

    Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades

    Proc Natl Acad Sci U S A

    (2005)
  • D.L. Miller et al.

    CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression

    J Leukoc Biol

    (1998)
  • J.R. Slupsky et al.

    Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40

    Thromb Haemost

    (1998)
  • K.S. Prasad et al.

    Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling

    Proc Natl Acad Sci U S A

    (2003)
  • Cited by (9)

    View all citing articles on Scopus
    View full text